期刊文献+

汉族脑梗死患者中氯吡格雷抵抗的相关因素研究 被引量:4

Related factors of clopidogrel resistance( CR) in Han patients with cerebral infarction
下载PDF
导出
摘要 目的探讨汉族脑梗死患者中氯吡格雷抵抗的相关因素。方法测定103例汉族脑梗死患者的血小板聚集率,分为氯吡格雷抵抗组和有效组,进行药物剂量、胰岛素抵抗、年龄、吸烟、高血压等因素的资料收集,并测定CYP2C19和P2Y12基因多态性,最后进行统计学分析。结果在氯吡格雷有效组和抵抗组,胰岛素抵抗差异无统计学意义(P>0.05),两组间性别、抽烟、高血压、血脂、BMI差异也无显著性(P>0.05),而氯吡格雷剂量、两种基因多态性均有统计学差异(P<0.05)。结论在汉族脑梗死患者中,氯吡格雷剂量、CYP2C19和P2Y12基因多态性是氯吡格雷抵抗的独立危险因素。而胰岛素抵抗、年龄、性别、抽烟、高血压、血脂、BMI与氯吡格雷抵抗可能无关。 Objective To explore the related factors of clopidogrel resistance(CR) in Han patients with cerebral infarction. Methods A total of 103 Han patients with cerebral infarction were divided into resistance group and effective group according to the platelet ag- gregation rate. The data of drug dose, insulin resistance ( IR), age, smoking, hypertension, and other risk factors were collected. The gene polymorphisms of CYP2C19 and P2Y12 were detected and analyzed. Results There was no statistical difference in IR, sex, smoking, hypertension, blood fat, BMI between resistance group and effective group( P 〉 0.05 ). The drug doses of clopidogrel and gene polymorphisms of CYP2C19 and P2Y12 were statistically different between two groups( P 〈 0. 05 ). Conclusion In Han patients with cerebral infarction, the doses of clopidogrel and the gene polymorphisms of CYP2C19 and P2Y12 are independent risk factors of CR, but IR, age, sex, smoking, hypertension, blood fat, BMI are not related to CR.
出处 《山西医科大学学报》 CAS 2013年第12期953-956,共4页 Journal of Shanxi Medical University
基金 西安医学院校基金资助项目(10FC19)
关键词 氯吡格雷抵抗 脑梗死 基因多态性 clopidogrel resistance cerebral infarction genetic polymorphisms
  • 相关文献

参考文献11

  • 1Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel:a re- view of the evidence [J].J Am Coil Cardiol,2005,45(8) :1157 - 1164.
  • 2李小鹰.阿司匹林在动脉硬化性心血管疾病中的临床应用:中国专家共识(2005)[J].中华心血管病杂志,2006,34(3):281-284. 被引量:194
  • 3Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome p450 3A4 metabolic activity to the phenomenon o f clopidogrel resistance [ J ]. Circulation, 2004, 109 (2) : 166 - 171.
  • 4李光伟,潘长玉,李晖.口服葡萄糖耐量试验葡萄糖、胰岛素曲线下面积比作为胰岛素敏感性指数的缺陷[J].中华内科杂志,1997,36(3):153-155. 被引量:39
  • 5Sambu N, Radhakrishnan A, Dent H ,et al. Personalised antiplate- let therapy in stent thrombosis: observations from the Clopidogrel Resistance in Stent Thrombosis (CREST) registry [ J ]. Heart, 2012,98(9) :706 -711.
  • 6Kara zniewiczLada M, Danielak D, Glowka F. Genetic and non- genetic factors affecting the response to clopidogrel therapy [ J ]. Exp Opin Pharmacother,2012,13 (5) :663 - 683.
  • 7Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events[ J]. N Engl J Med,2009,360(4) :363 - 375.
  • 8Ades PA, Savage PD, Toth M J, et al. The influence of obesity and consequent insulin resistance on coronary risk factors in medically treated patients with coronary disease [ J ]. Int J Obes, 2008,32 : 967 - 974.
  • 9庞国珍,高汉华,黄石安,王焱.氯吡格雷抵抗相关因素分析[J].实用药物与临床,2012,15(2):82-85. 被引量:14
  • 10Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopi- dogrel[ J]. CMAJ,2009,180(7) :713 -718.

二级参考文献29

  • 1李光伟,Step.,L.检测人群胰岛素敏感性的一项新指数[J].中华内科杂志,1993,32(10):656-660. 被引量:2125
  • 2Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothromboric events in patients with acute myocardial infarction [ J ]. Circulation, 2004,109 : 3171-3175.
  • 3Frere C, Cuisset T, Morange PE. Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome [ J ]. Am J Cardiol, 2008, 101:1088-1093.
  • 4Gurbel PA,Bliden KP,Hiatt BL,et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivily [ J ]. Circulation, 2003, 107 : 2908 -2913.
  • 5Wenaweser P, Dorffler-Melly J, Imboden K, et al. Stent thrombosis is associated with an impaired response to antplatelet therapy[ J]. J Coil Cardiol,2005,45:1748-1752.
  • 6Wiviot SD, Trenk D, Frelinger AL. Prasugrel compared with high loading and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation thrombolysis in myocardial infarction 44 trial [ J ]. Circulation, 2007,116 ( 25 ) : 2923 -2932.
  • 7Ades PA, Savage PD, Toth MJ, et al. The influence of obesity and consequent insulin resistance on coronary risk factors in medically treated patients with coronary disease[ J]. Int J Obes, 2008,32:967-974.
  • 8李光伟,中华心血管病杂志,1996年,24卷,57页
  • 9李光伟,中华内科杂志,1993年,32卷,656页
  • 10吴京兰,中华心血管病杂志,1993年,21卷,272页

共引文献244

同被引文献37

引证文献4

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部